Canada’s Apotex Donates Critical N95 Masks to Support Frontline Healthcare Workers
Apr 17, 2020Toronto, Ontario, April 17, 2020 – Apotex Pharmachem, Canada’s largest producer of active pharmaceutical ingredients, has donated thousands of much-needed N95 masks for use by frontline healthcare workers across the GTA.
The facility, located in Brantford, Ontario, maintains a regular supply of N95 masks which must be worn by certain site employees to perform their regular duties, including those in manufacturing and quality control.
As the demand for masks has surged from the impact of COVID-19, Apotex Pharmachem heeded the call for help. By modifying its internal procedures, the company adapted its use of Personal Protection Equipment. This enabled the site to free up some of their surplus inventory of N95 masks.
Eight hundred masks were provided to the City of Brantford which coordinated the distribution of donated supplies to the local healthcare system including hospitals and Emergency Medical Services (EMS). An additional 800 masks were shared between GTA-based Trillium Health Partners and William Osler Health System, which serve Brampton and part of Etobicoke. The most recent donation of 400 masks was made to Children’s Health Foundation which supports the Children’s Hospital at London’s Health Sciences Centre.
“In these challenging times it is so important for the community to come together and provide support,” said Jason Fischer, Vice-President & GM, “and while we had a limited number of masks that we could donate, every bit helps. Our incredibly dedicated healthcare workers are facing an unprecedented challenge fighting the COVID-19 virus. These masks are essential to keeping them safe as they serve patients and Apotex is committed to helping in whatever way we can.”
Part of the Apotex group of companies, Apotex Pharmachem manufactures active pharmaceutical ingredients used in pharmaceutical manufacturing and employs over 300 people.
About Apotex Inc.
Apotex Inc. is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines for patients around the world. Apotex employs almost 8,000 people worldwide in manufacturing, R&D, and commercial operations. Apotex Inc. exports to more than 100 countries and territories and operates in more than 45 countries, with a significant presence in Canada, the US, Mexico, and India. Through vertical integration, Apotex is comprised of multiple divisions and affiliates including Apotex Inc., focused on generics; Apobiologix, a division of Apotex Inc. focused on biosimilar development; Aveva, an affiliate of Apotex Inc. fully integrated global developer and manufacturer of complete transdermal solutions; Apotex Consumer Products, a division of Apotex Inc. focused on brand name products; and Global Active Pharmaceutical Ingredients (GAPI), a division of Apotex Inc. focused on the manufacturing of active pharmaceutical ingredients (API) for Apotex and third parties. For more information visit: www.apotex.com.
-30-
All media enquiries:
Jordan Berman
Vice-President, Global Corporate Affairs
PH: 416-401-7487
Mobile: 647-272-2287
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Jul 2, 2025
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
Apotex Inc., the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization.
-
May 25, 2025
Apotex launches nilotinib capsules, the first generic version of Tasigna®¹ in the United States, with 180 days of exclusivity
Nilotinib is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia ("Ph+ CML") in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and pediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments.
-
May 20, 2025
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.